CBu-Cit-GAL-02-221
CBu-Cit-GAL-02-221 is a PROTAC that degrades BRD4 by association with cBu-Cit. cBu-Cit-GAL-02-221 can effectively inhibit BRD4 in HER2 positive and negative breast cancer cell lines. cBu-Cit-GAL-02-221 has a single bond and can be conjugated to an ADC antibody to form a PAC[1].
Product Specifications
CAS Number
2417369-73-2
Product Name Alternative
CBu-Cit-PROTAC BRD4 Degrader-5
UNSPSC
12352005
Target
Epigenetic Reader Domain; PROTAC-Linker Conjugates for PAC
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cbu-cit-protac-brd4-degrader-5.html
Smiles
CC1=C(C)SC(N2C3=NN=C2C)=C1C(C4=CC=C(C=C4)Cl)=N[C@H]3CC(NCCOCCOCCOCC(N[C@H](C(N5C[C@@H](C[C@H]5C(NCC(C=C6)=CC=C6C7=C(C)N=CS7)=O)OCNC(OCC8=CC=C(NC([C@@H](NC(C9(C(NCCCCCN%10C(C=CC%10=O)=O)=O)CCC9)=O)CCCNC(N)=O)=O)C=C8)=O)=O)C(C)(C)C)=O)=O
Molecular Formula
C79H99ClN16O16S2
Molecular Weight
1628.31
References & Citations
[1]Peter S Dragovich, et al. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties. J Med Chem. 2021 Mar 11;64 (5) :2534-2575.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog